Perspective Therapeutics, Inc. (CATX) — Company Research

Last Updated: 16 May 2026

Perspective Therapeutics, Inc. (NYSE American: CATX) is a Seattle-based radiopharmaceutical development company pioneering precision targeted alpha therapy (TAT) for cancer treatment. The company is building a proprietary platform centred on lead-212 (²¹²Pb), an alpha-emitting isotope that delivers high-energy, short-range radiation directly to cancer cells. Its lead programme, VMT-α-NET, is advancing through Phase 1/2a clinical trials targeting somatostatin receptor 2-positive neuroendocrine tumours, with a registration-enabling trial pathway under active regulatory discussion. With three clinical-stage programmes, a proprietary radioisotope generator, and $271 million in cash following a February 2026 equity offering, the company is among the few pure-play targeted alpha therapy developers listed on a US exchange.

1. Company Snapshot

Field	Value
Full name	Perspective Therapeutics, Inc.
Ticker	CATX
Exchange	NYSE American (AMEX)
Sector / Industry	Healthcare — Radiopharmaceuticals / Biotechnology
Founded	2004 (as Isoray, Inc.); rebranded February 2022; merged with Viewpoint Molecular Targeting February 2023
Headquarters	Seattle, Washington, USA
CEO	Thijs (Johan) Spoor (appointed February 2023)
Employees	~166 (as of April 2026; per company filings)
Market cap	~$434M (at ~$3.81/share, 114M shares; May 2026)
Revenue (FY2025)	$0.9M (NIH grant revenue; company is pre-commercial)
Net loss (FY2025)	$(103.1M) GAAP (per FY2025 press release, March 2026)
Cash & investments	$271M (Q1 2026 end, per Q1 2026 press release, May 2026)
Cash runway	Into late 2027 (per management guidance)
Website	perspectivetherapeutics.com

2. Bull Case vs Bear Case

Distilled from the full report below — factual only, no ratings.

Bull Case

• Alpha advantage over approved beta therapies: ²¹²Pb emits alpha particles with ~100× greater linear energy transfer than beta emitters such as Lu-177. Alpha particles travel only 2–10 cell diameters, delivering concentrated lethal doses while sparing surrounding tissue. No approved ²¹²Pb drug exists, placing Perspective in first-mover position in this specific modality.
• VMT-α-NET clinical momentum: At AACR April 2026, updated data showed 43% objective response rate in Cohort 2 evaluable patients; by late 2026, all 46 Cohort 2 patients will have had 60 weeks of follow-up. Sanofi discontinued its competing SSTR2-targeted alpha agent Alphamedix in 2025, leaving Perspective as the only ²¹²Pb programme in this indication.
• Extended cash runway post-offering: The February 2026 offering raised approximately $164M net, bringing cash and investments to $271M as of 31 March 2026. Management states this is sufficient to fund operations into late 2027, covering key VMT-α-NET regulatory milestones and data readouts across all three programmes.
• Proprietary manufacturing moat: The company’s ²²⁴Ra/²¹²Pb generator platform is a structural differentiator — difficult and capital-intensive for competitors to replicate. A regional supply network is under construction (Chicago flagship completing 2026; LA site in development) to enable ready-to-administer clinical and commercial supply.
• Multi-programme optionality: Three Phase 1/2a programmes (VMT-α-NET NETs, VMT01 melanoma, PSV359 FAP+ solid tumours) plus first-in-human imaging data for PSV594 (CCK2R-targeted) presented May 2026 diversify binary clinical risk.

Bear Case

• Clinical-stage binary risk: All three programmes remain in Phase 1/2a. No product has regulatory approval. A registrational trial design for VMT-α-NET has not yet been submitted to the FDA; the company states only it expects “meaningful regulatory engagement in 2026.” Clinical failures or FDA disagreement on trial design could materially delay or end any programme.
• Sustained and accelerating dilution: Common shares outstanding rose from ~64M (FY2024 weighted avg) to 114M by 31 March 2026, a ~78% increase in one year. The February 2026 offering issued 39.6M shares at $3.79. Additional equity raises are likely before any potential commercialisation.
• Accelerating cash burn: R&D expenses doubled from $41.6M in FY2024 to $84.2M in FY2025. Q1 2026 net loss of $26.2M implies an annualised burn rate of approximately $105M+. Manufacturing build-out is adding capex on top of operating losses.
• Manufacturing execution risk: The company is simultaneously running three clinical trials and constructing a multi-site regional manufacturing network. Construction delays, supply disruptions, or regulatory hurdles at manufacturing sites could impair clinical timelines and require additional capital.
• Large-pharma competitive threat: Novartis (>$2B in RPT revenues), BMS (RayzeBio acquisition $4.1B), AstraZeneca (Fusion Pharma), and Eli Lilly (Point Biopharma) have far greater resources and are actively expanding radiopharmaceutical pipelines. Competitive displacement remains a material risk.

3. What Does This Company Actually Do?

Perspective Therapeutics is developing a new class of cancer drugs called targeted alpha therapies (TATs). The concept: pair a radioactive isotope that emits alpha particles with a targeting molecule that seeks out a specific protein expressed on cancer cells, and you get a radiopharmaceutical that travels through the bloodstream, homes in on tumour cells, and irradiates them from the inside while largely sparing healthy tissue.

The company’s differentiating choice of isotope is lead-212 (²¹²Pb). Alpha particles have roughly 100 times the linear energy transfer of the beta particles used by established radiopharmaceuticals such as Lutathera and Pluvicto. They also travel only two to ten cell diameters in tissue, making them far more locally precise. ²¹²Pb is short-lived (half-life approximately 10.6 hours) and decays through a chain that delivers an alpha particle at the tumour site. The company has developed a proprietary ²²⁴Ra/²¹²Pb generator platform to produce ²¹²Pb on-site or near-site, building a regional supply infrastructure.

Each targeting peptide can be labelled with either a diagnostic isotope (²⁰³Pb or ⁶⁸Ga) for imaging and patient selection, or with ²¹²Pb for therapy. This “theranostic” approach allows clinicians to confirm a patient’s tumour expresses the target receptor before administering the therapeutic dose — personalising treatment and improving the probability of response.

The company is pre-commercial. Its only current revenue is grant income from NIH-funded research ($884K in FY2025). All three clinical programmes are in Phase 1/2a dose-finding studies in the United States.

Segment	% of revenue	What it is
NIH Grant Revenue	100% ($0.9M FY2025)	Research grant income from the National Institutes of Health, supporting translational research activities on the 212Pb platform. This is the sole revenue line. The company is pre-commercial; all clinical programmes are pre-approval and pre-revenue. Geographic breakdown not applicable.

Note: company is pre-commercial; no operating product segments exist. Upon potential approval and launch of VMT-α-NET, the primary commercial segment would be neuroendocrine tumour treatment. Additional potential segments would follow from VMT01 (melanoma) and PSV359 (solid tumours) approvals.

4. The Business Model

How a clinical-stage radiopharmaceutical company funds itself. Perspective Therapeutics does not yet generate product revenue. It funds operations through equity capital raises and NIH grant income. The February 2026 underwritten offering raised approximately $164M net proceeds through the issuance of 39.6M shares at $3.79 per share, along with pre-funded warrants for a further 6.6M shares. Prior to this, the February 2023 merger between Viewpoint Molecular Targeting, Inc. and Isoray, Inc. was the founding equity event for the current entity. Future funding before commercialisation is expected to require additional equity or partnership arrangements.

Unit economics (projected, not yet achieved). The commercial model, if VMT-α-NET receives regulatory approval, would be a hospital-facing radiopharmaceutical treatment course. Comparables include Novartis’s Lutathera (list price approximately $130,000 per course for NETs) and Pluvicto (approximately $42,500 per dose, typically 6 doses for prostate cancer). Gross margins for approved branded radiopharmaceuticals are typically high (60–80%+) once manufacturing overhead is absorbed at scale. The company’s regional manufacturing approach is designed to reduce the logistics cost and spoilage risk associated with the short half-life of ²¹²Pb.

Moat. The proprietary ²²⁴Ra/²¹²Pb generator technology creates an internal isotope supply chain that is capital-intensive and time-consuming to replicate. The clinical data package being assembled for VMT-α-NET — across three dose cohorts, with theranostic patient selection, in a rare indication with high unmet need — represents a regulatory filing asset that competitors could only reproduce by running equivalent multi-year trials. Intellectual property around the ²¹²Pb platform chemistry and targeting peptide conjugation provides additional protection, per the company’s 10-K disclosures.

Subsidies and regulatory credits. Perspective receives NIH grant funding for specific research activities ($884K in FY2025, $1.45M in FY2024). This is not a material portion of operational funding. No government production subsidies or tax credits for the manufacturing network were identified in the company’s filings reviewed during this session. The company has benefited from the Deferred Income balance of $26.6M on its noncurrent balance sheet — this is a non-cash government-related deferred revenue item recorded as part of the Viewpoint/Isoray merger and relates to prior DoE/NIH-related contractual arrangements; it is not recurring operational revenue.

Isotope supply chain. ²¹²Pb is produced from the decay of radium-224, which is derived from thorium-228. The upstream isotope supply chain is constrained globally; most radium-224 is sourced from a small number of facilities. Perspective’s proprietary generator system is designed to bring production closer to the point of patient administration, addressing the key logistics challenge of the isotope’s ~10.6-hour half-life. The Chicago flagship manufacturing site is expected to complete construction in 2026; a Los Angeles site is also in development.

5. Financial Health

Note: Perspective Therapeutics is a pre-commercial clinical-stage company. Standard financial metrics — gross margin, operating margin, P/E, EV/EBITDA — are not applicable in the conventional sense. The key financial indicators are cash position, burn rate, and capital runway. All FY2025 figures sourced directly from the company’s FY2025 press release (GlobeNewswire, 16 March 2026, primary source). Q1 2026 figures from Q1 2026 press release (GlobeNewswire, 11 May 2026, primary source). FY2024 figures cross-referenced from the FY2025 comparative income statement. Revenues shown are NIH grant revenues only; not product revenues.

FCF = operating cash flow minus capital expenditure. As a pre-commercial company, FCF is deeply negative. In FY2025, total cash and short-term investments declined from approximately $227M to $145M, a reduction of approximately $82M. This reflects the combined effect of operating losses offset by non-cash items and working capital movements, plus approximately $19M in net property and equipment additions (manufacturing capex). In Q1 2026, PP&E increased by a further $15.9M to $92.5M, reflecting accelerated manufacturing build-out. The company does not separately report an operating cash flow statement summary in its quarterly press releases; full cash flow statements are available in the 10-K (filed March 2026) and 10-Q (filed May 2026) on SEC EDGAR.

Fiscal year	Revenue (grant, $M)	YoY %	GAAP EPS (diluted)	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021	$0	N/M	—	—	$0	—
FY2022	~$0	N/M	~$(0.80) ¹	—	$0	—
FY2023	~$1.4M ²	N/M	$(1.74) ²	—	$0	~$1.7M note ²
FY2024	$1.5M	+7%	$(1.23)	—	$0	$1.6M note ³
FY2025	$0.9M	−40%	$(1.40)	—	$0	$1.6M note ³

¹ FY2022 EPS shown is post-1:10 reverse stock split basis (split effected June 2024). FY2022 was the final year of the legacy Isoray, Inc. entity prior to the February 2023 merger with Viewpoint Molecular Targeting. EPS figure from search aggregators; primary source not retrieved during this session. Net loss FY2022 approximately $10.8M.

² FY2023 net loss approximately $46.5M; EPS $(1.74) post-split adjusted. First full year as Perspective Therapeutics (post February 2023 merger). Data from search aggregators; primary press release not directly retrieved during this session. LT debt is noncurrent note payable, not traditional bond debt; exact FY2023 balance estimated.

³ LT debt column denotes “note payable, net of current portion” per audited balance sheets: $1.625M (FY2024) and $1.569M (FY2025), per FY2025 annual press release (primary source). No traditional bond or bond-equivalent debt exists. Adjusted EPS not reported; company does not publish non-GAAP EPS as a clinical-stage entity. GAAP EPS includes all items, including the $10M non-cash preclinical asset impairment in Q4 2025 and $24M goodwill impairment in FY2024.

Quarterly breakdown (most recent first):

Quarter	Revenue (grant)	Operating EPS	GAAP EPS
Q1 2026	$0.08M	$(0.25)	$(0.25)
Q4 2025	est. ~$0.18M ⁴	$(0.51) ⁴	$(0.51) ⁴
Q3 2025	est. ~$0.18M ⁴	$(0.35)	$(0.35)
Q2 2025	est. ~$0.18M ⁴	$(0.29) ⁴	$(0.29) ⁴
Q1 2025	$0.34M	$(0.25)	$(0.25)
FY2025 Total	$0.88M	—	$(1.40)

⁴ Q4 2025 EPS derived as FY2025 $(1.40) minus nine-month $(0.89) = $(0.51). Q2 2025 EPS derived as nine-month $(0.89) minus Q1 $(0.25) minus Q3 $(0.35) = $(0.29). Q3 and Q1 2025 EPS from primary sources (Q3 2025 press release; Q1 2026 press release comparative). Q2–Q4 grant revenue estimated as FY2025 total $884K minus Q1 $342K divided three ways; exact quarterly split not individually disclosed. Q4 2025 EPS includes $10M non-cash impairment loss on deprioritised preclinical asset.

Cash and liquidity: As of 31 March 2026: cash $54.0M + short-term investments $217.0M = $271M total. Net tangible assets as of 31 March 2026: total assets $410.8M, total liabilities $63.3M, total stockholders’ equity $347.4M. No bank debt, no revolving credit facility disclosed.

6. Valuation & Market Data

Raw metrics, May 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	~$434M (at ~$3.81/share × 114M shares; May 2026)
Enterprise value	~$165M (market cap ~$434M + note payable ~$1.6M − cash & investments $271M; May 2026)
Trailing P/E (GAAP)	N/A (net loss; GAAP EPS $(1.40) FY2025)
P/E (forward)	N/A (no earnings forecast meaningful for pre-commercial clinical company)
P/S (TTM)	N/M (grant revenue $0.88M FY2025; not a product revenue metric)
EV/EBITDA (TTM)	N/A (negative EBITDA; pre-commercial)
P/FCF	N/A (negative FCF)
52-week high	$6.16
52-week low	$1.96
Current price	~$3.81 (13 May 2026; approximately 38% below 52-week high, 94% above 52-week low)
Short interest (% of float)	~10.0–11.1% of float (~10.1M shares short; May 2026)
Days to cover	Data not available — verify at finra.org short interest data
Dividend	None; no dividend paid or declared

Note: Standard valuation multiples (P/E, P/S, EV/EBITDA, P/FCF) are not meaningful for a pre-commercial clinical-stage company with sub-$1M in non-product revenues. The negative enterprise value (~$165M) reflects that cash and investments significantly exceed market capitalisation net of debt — a common feature of well-funded pre-commercial biotechs. The relevant investor framework is cash runway versus clinical milestones, not earnings multiples.

7. What Are They Building / What’s Coming?

Perspective has four programmes at varying stages of development, all centred on the same ²¹²Pb alpha therapy platform.

VMT-α-NET (lead programme — neuroendocrine tumours). Phase 1/2a multi-centre open-label dose-finding study (NCT05636618) of [²¹²Pb]VMT-α-NET in unresectable or metastatic SSTR2-positive neuroendocrine tumour patients who have not received prior radiopharmaceutical therapy. Three dose cohorts have been completed: Cohort 1 (2.5 mCi, 2 patients), Cohort 2 (5.0 mCi, 46 patients, now closed), and Cohort 3 (6.0 mCi, 20 patients, now closed). Cohort 4 is open for recruitment. Updated data presented at AACR in April 2026 (data cut-off 4 March 2026) showed 43% objective response rate in Cohort 2 evaluable patients, across 64 patients in the safety population with no dose-limiting toxicities or Grade 5 events. As of 30 April 2026, the first 23 Cohort 2 patients have had at least 60 weeks of follow-up; all 46 Cohort 2 patients are expected to have 60 weeks of follow-up by late 2026. The company states it believes its “data package positions us for meaningful regulatory engagement in 2026 to align on the path forward” for a registrational trial. A proof-of-concept cohort in meningioma patients has also been opened, citing potential for an expedited development path given the absence of approved systemic therapies for this disease (per Q1 2026 press release, 11 May 2026).

VMT01 (Phase 1/2a — melanoma). VMT01 targets the melanocortin-1 receptor (MC1R) expressed on melanoma cells. The Phase 1/2a study (NCT05655312) evaluates VMT01 as monotherapy at 3.0 mCi and in combination with nivolumab (BMS’s Opdivo, a PD-1 checkpoint inhibitor) at 3.0 mCi, in heavily pre-treated patients with histologically confirmed melanoma and MC1R-positive imaging scans. As of February 28, 2026, 10 patients had received VMT01 3.0 mCi treatment (6 combo, 4 mono). Both cohorts are now closed for enrolment. By late 2026, these 10 patients will have had at least 24 weeks of follow-up sufficient for at least one post-treatment scan. A clinical data update is expected to be submitted for presentation at a medical conference in 2026 (per management, FY2025 press release, 16 March 2026).

PSV359 (Phase 1/2a — FAP-positive solid tumours). PSV359 targets fibroblast activation protein-alpha (FAP-α), expressed across multiple high-prevalence solid tumours including colorectal, pancreatic, lung, and breast cancers. As of 30 April 2026, nine patients have been dosed (2 in Cohort 1 at 2.5 mCi; 7 in Cohort 2 at 5.0 mCi), with Cohort 3 now open for recruitment. By late 2026, the dosed patients will have had at least 32 weeks of follow-up — sufficient for at least one post-full-treatment scan. Initial Phase 1 data expected at medical conferences in late 2026 (per Q1 2026 press release, 11 May 2026).

PSV594 (preclinical / first-in-human imaging stage — CCK2R-targeted). In May 2026, Perspective presented first-in-human imaging data for PSV594, designed to target the cholecystokinin-2 receptor (CCK2R), expressed across several hard-to-treat cancers. Both preclinical and first-in-human images demonstrate clean, precise tumour uptake with limited kidney retention, suggesting a potentially favourable therapeutic index. The company states that if this construct meets development criteria, pre-IND filing activities will follow (per Q1 2026 press release, 11 May 2026).

Manufacturing infrastructure. The company is building a regional supply network for finished drug product candidates, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform. The Chicago-area flagship site is on track to complete construction in 2026. A Los Angeles-area complementary site is under development. Management stated in the Q1 2026 press release that it has “plans beyond our current footprint.” This infrastructure is designed to support both clinical supply for ongoing trials and, if products receive approval, commercial operations. Capital expenditure on property and equipment was approximately $19M net in FY2025 and approximately $15.9M net in Q1 2026 alone, reflecting the pace of the build-out.

8. Competitive Landscape

The global radiotheranostics market was valued at approximately $4.75B in 2025 and is projected to reach approximately $44B by 2034, at a ~28% CAGR (Fortune Business Insights, 2026). The targeted alpha therapy segment was approximately $1.0B in 2025, growing at ~17% annually. Perspective competes both directly in specific tumour indications and broadly for capital, talent, isotope supply, and clinical infrastructure against larger and better-resourced players.

SSTR2/NETs competitive dynamics: Novartis’s Lutathera ([¹⁷⁷Lu]Lu-DOTATATE) is the current standard of care for SSTR2+ NETs, generating over $1B in annual revenue. Lutathera is a beta emitter. Perspective positions VMT-α-NET as an alpha-based next-generation option for patients with heterogeneous SSTR2 expression or progression on beta therapy. Sanofi’s Alphamedix, a competing SSTR2-targeted alpha therapy, was discontinued in 2025, leaving Perspective as the only lead-212-based programme in this indication.

Alpha therapy landscape: Bayer’s Xofigo (radium-223 dichloride) is the only currently approved targeted alpha therapy globally, for bone-metastatic castration-resistant prostate cancer. It uses a different mechanism, different target, and no theranostic imaging component, but established the regulatory precedent for approved alpha therapy. BMS (via its $4.1B acquisition of RayzeBio in January 2024) is developing actinium-225-based targeted alpha therapies — a different alpha isotope from Perspective’s ²¹²Pb. AstraZeneca (via Fusion Pharma) and Eli Lilly (via Point Biopharma, acquired for ~$1.4B in 2023) have also committed substantial capital to the radiopharmaceutical space.

Peer	Market Cap (May 2026)	FY2025 Revenue	P/E (TTM, May 2026)	Primary RPT product / differentiator
Novartis (NVS)	~$230B	~$45B total; Lutathera+Pluvicto >$2B combined (per Novartis 2025 annual report)	~18x	Lutathera (Lu-177, SSTR2, NETs — approved) and Pluvicto (Lu-177, PSMA, prostate cancer — approved). Large pharma scale. Principal commercial competitor in the NETs indication Perspective is targeting.
Bayer (BAYRY)	~$16B	~€46B total; Xofigo ~€600M (per Bayer 2025 annual report)	~14x	Xofigo (Ra-223 alpha emitter, bone-met CRPC — approved). Only currently approved targeted alpha therapy globally; different target and indication from Perspective, but the established regulatory and clinical precedent for the modality.
Lantheus Holdings (LNTH)	~$4.9B	$1.54B (per Lantheus FY2025 press release)	~20x	PYLARIFY (PSMA PET diagnostic imaging, prostate cancer). Primarily a diagnostics business with therapeutic pipeline ambitions. Competes for capital, clinical infrastructure, and institutional attention in the radiopharmaceutical space.
Perspective Therapeutics (CATX)	~$434M	$0.9M grant revenue (pre-commercial; per FY2025 press release)	N/A	[212Pb]-based targeted alpha platform; VMT-α-NET (NETs, Phase 1/2a), VMT01 (melanoma), PSV359 (solid tumours). Only 212Pb clinical programme in SSTR2+ NETs after Sanofi’s Alphamedix discontinuation.

Market cap figures from web searches during this session (May 2026). Revenue figures from publicly reported annual results; Novartis and Bayer revenues include all business segments. Government subsidies to Bayer and Novartis are not identified as material to their radiopharmaceutical divisions based on available public disclosure. Exact RPT sub-segment revenues are disclosed within larger company filings.

9. Leadership and Ownership

CEO: Thijs (Johan) Spoor. Appointed President and CEO in February 2023 at the time of the Viewpoint Molecular Targeting/Isoray merger. Spoor came from the Viewpoint side of the transaction and was central to the strategic vision behind the ²¹²Pb radiopharmaceutical platform. He previously held commercial and executive roles at Jubilant Radiopharma and Sofie Biosciences and remains a Board Director. He presented at the J.P. Morgan Healthcare Conference in January 2026, reaffirming the company’s clinical strategy (per Seeking Alpha transcript).

CMO: Marcus Puhlmann. Chief Medical Officer, responsible for clinical development across all three programmes. Joined post-merger. Received 150,000 stock options as annual equity award in March 2026 (per Form 4).

CFO: Joel Sendik. Chief Financial Officer; present at investor conferences alongside the CEO and CMO. Responsible for capital structure, fundraising, and financial reporting.

Board of Directors (2026 Annual Meeting slate, per DEF 14A proxy filed 2026): Thijs Spoor (CEO/Director), Lori A. Woods (Independent), Heidi Henson (Independent), Robert F. Williamson III (Independent), Frank Morich (Independent), Maya Martinez-Davis (Independent). The 2026 Annual Meeting is scheduled for 27 May 2026.

Major institutional shareholders (per 13F/13G filings and search data, May 2026): BlackRock ~6.1%; Qatar Investment Authority (Qatar Holding LLC) ~6.2% (7.07M shares; per Schedule 13G filed February 2026); TCG Crossover Management ~6.9% (per 13G); The Vanguard Group ~4.7%; Morgan Stanley ~2.6% (reduced from >5%, per Schedule 13G/A filed May 2026). Lantheus Holdings is also cited as a strategic holder, reflecting the theranostics ecosystem investment thesis.

Insider transactions (SEC Form 4 filings, September 2025 — March 2026):

Name	Date	Type	Shares	Price	Value	Plan Type
Marcus Puhlmann (CMO)	02 Mar 2026	Grant (options)	150,000	$0 exercise	2026 annual equity award	Compensation grant
Robert F. Williamson III (Director)	02 Mar 2026	Grant (options)	50,000	$0 exercise	2026 annual director award; vests 02 Mar 2027	Compensation grant
Lori A. Woods (Director)	02 Mar 2026	Grant (options)	50,000	$0 exercise	2026 annual director award	Compensation grant
Maya Martinez-Davis (Director)	02 Mar 2026	Grant (options)	50,000	$0 exercise	2026 annual director award; vests 02 Mar 2027	Compensation grant
Frank Morich (Director)	02 Mar 2026	Grant (options)	50,000	$0 exercise	2026 annual director award	Compensation grant
Maya Martinez-Davis (Director)	03 Sep 2025	Grant (options)	75,000	$3.38	Vests monthly over 36 months	Compensation grant

All transactions are compensation-related equity grants (stock options), not discretionary open-market purchases or 10b5-1 plan sales. No discretionary insider buying or selling identified in Form 4 searches during this session. For complete transaction history, verify at SEC EDGAR (sec.gov, search CATX Form 4).

10. Risks and Challenges

• Clinical trial failure (Operational): All three programmes are in Phase 1/2a. Oncology drug development failure rates for Phase 2 exceed 50% historically. An unexpected safety signal, lack of efficacy, or results insufficient for a registrational trial would materially impair the company’s value and require full strategic re-evaluation.
• Regulatory path uncertainty (Regulatory): The company has not yet agreed a registrational trial design with the FDA for VMT-α-NET. The company states it believes its data package supports “meaningful regulatory engagement in 2026.” The FDA may request additional cohorts, longer follow-up, a different control arm, or alternative patient selection criteria, potentially adding years to the development timeline and consuming additional capital.
• Ongoing shareholder dilution (Financial): Common shares outstanding increased ~78% in approximately one year (64M weighted average FY2024 to 114M by 31 March 2026). With no commercial revenue and a cash runway through late 2027, additional equity raises are probable before any potential product approval. The company has no committed credit facility disclosed in its filings.
• Cash burn acceleration (Financial): R&D expenses doubled from $41.6M in FY2024 to $84.2M in FY2025. Q1 2026 net loss of $26.2M implies an annualised run rate of approximately $105M. Manufacturing capex of approximately $15.9M in Q1 2026 alone adds to cash consumption beyond operating losses. If timelines slip or clinical activity increases further, the late-2027 cash runway estimate could compress.
• Manufacturing execution and cost risk (Operational): Building a multi-site regional radiopharmaceutical manufacturing network in parallel with running three clinical trials is operationally complex. Construction delays, regulatory clearances for manufacturing sites, supply constraints in the ²²⁴Ra feedstock, or cost overruns could impair clinical timelines and require additional capital.
• Isotope supply chain concentration (Concentration): ²¹²Pb is derived from radium-224, produced at a small number of nuclear facilities globally. Disruption to upstream isotope supply through regulatory action, geopolitical events, or facility incidents could halt clinical trials and constrain commercial supply indefinitely.
• Large-pharma competitive displacement (Competitive): BMS (RayzeBio acquisition, Ac-225 platform), AstraZeneca (Fusion Pharma), Novartis (RPT expansion), and Eli Lilly (Point Biopharma) have collectively committed billions of dollars to radiopharmaceutical development. Competitive displacement from a better-resourced programme achieving earlier Phase 3 readout in SSTR2+ NETs would erode VMT-α-NET’s first-mover positioning.
• Key person risk (Operational): The company employs approximately 166 people and its programmes depend on a concentrated senior leadership team. Loss of CEO Thijs Spoor, CMO Marcus Puhlmann, or critical scientific personnel would likely disrupt programme execution and could affect the stock price materially, given the small size of the team relative to operational scope.
• Payer and reimbursement uncertainty (Commercial): Even upon potential regulatory approval, payers (CMS, NICE, other national bodies) must agree to reimburse at a price that supports the commercial model. Radiopharmaceutical reimbursement decisions involve complex logistics, hospital infrastructure requirements, and treatment pathway positioning. A low reimbursed price or restricted access pathway would substantially reduce peak revenue potential.
• Short interest elevation (Market): Short interest of approximately 10–11% of float is elevated for a small-cap biotech, suggesting a segment of the market is positioned for a price decline. This creates binary risk around clinical data readouts: a positive result may trigger a short squeeze; a disappointing result could be amplified by additional short selling.

11. Recent Developments

• 11 May 2026 — Q1 2026 results and business update published. Net loss $26.2M ($0.25/share); R&D expenses $21.4M (+50% year-over-year); G&A $7.0M; cash and investments $271M. All three clinical programmes confirmed on track. Cohort 4 of VMT-α-NET now open for recruitment. First-in-human PSV594 imaging data publicly presented. All Cohort 2 patients expected to have 60-week follow-up by late 2026 (per GlobeNewswire, 11 May 2026).
• May 2026 — PSV594 first-in-human imaging data presented. Perspective presented FIH imaging data for PSV594, its CCK2R-targeted candidate. Images show clean, precise tumour uptake with limited kidney retention, suggesting a favourable therapeutic index for potential clinical development. This is the first public human imaging data for this asset (per Q1 2026 press release, 11 May 2026).
• 20 Apr 2026 — Updated VMT-α-NET data at AACR Annual Meeting 2026. Data cut-off 4 March 2026; additional ~12 weeks of follow-up versus ASCO-GI January 2026 data. Safety analysis in 64 patients across all three cohorts: no DLTs, no Grade 5 events, Grade ≥3 events in 37.5% of patients. Updated 43% ORR in Cohort 2 evaluable patients. First 23 Cohort 2 patients had at least 48 weeks of follow-up as of 30 April 2026 (per GlobeNewswire, 20 April 2026).
• Feb 2026 — $164M underwritten equity offering completed. 39.6M shares issued at $3.79/share plus pre-funded warrants for 6.6M additional shares. Net proceeds approximately $164M. Shares outstanding increased from ~74.3M (YE 2025) to ~114M by 31 March 2026. Cash position increased from $145M (YE 2025) to $271M (31 March 2026), extending management’s cash runway guidance to late 2027 (per FY2025 press release, 16 March 2026).
• 16 Mar 2026 — Full year 2025 results reported. Net loss $103.1M ($1.40/share); R&D $84.2M (doubles year-over-year, including $10M non-cash impairment on deprioritised preclinical asset); G&A $30.2M; cash and investments $145M at year end. Shares outstanding 74.3M at 31 December 2025 (per GlobeNewswire, 16 March 2026, primary source).
• 09 Jan 2026 — VMT-α-NET data at ASCO Gastrointestinal Cancers Symposium. Updated data with data cut-off 10 December 2025. In 56-patient safety population: no DLTs, no Grade 5 events. In 25 evaluable patients (Cohorts 1 and 2): 19/25 (76%) without progression and alive; 9/23 Cohort 2 patients (39%) achieved objective response per RECIST v1.1; seven patients showed deepening of best response versus prior ESMO 2025 update (per GlobeNewswire, 9 January 2026).

12. Key Dates Coming Up

• 27 May 2026 — Annual Meeting of Stockholders, Sheraton Grand Chicago Riverwalk, Chicago. Agenda includes director elections (slate: Spoor, Woods, Henson, Williamson, Morich, Martinez-Davis), executive compensation vote, and auditor ratification (per DEF 14A proxy, 2026).
• Expected August 2026 — Q2 2026 earnings release and business update (exact date not yet confirmed; verify at perspectivetherapeutics.com/investors).
• Expected late 2026 — VMT-α-NET Cohort 2 full 60-week follow-up dataset. All 46 Cohort 2 patients expected to have 60 weeks of follow-up by late 2026. This is the key dataset the company expects will support FDA engagement on a registrational trial pathway.
• Expected late 2026 — VMT-α-NET Cohort 3 DLT patients 48-week follow-up. The eight DLT-assessment patients in Cohort 3 (6.0 mCi) are expected to have 48 weeks of follow-up by late 2026. This data will contribute to the full clinical evidence package.
• Expected late 2026 — VMT01 melanoma data readout (24-week follow-up). The 10 patients dosed at 3.0 mCi since September 2025 (mono and combo with nivolumab) will have had at least 24 weeks of follow-up by late 2026. Clinical update expected at a medical conference.
• Expected late 2026 — PSV359 initial Phase 1 data. Nine dosed patients (Cohorts 1 and 2) expected to have at least 32 weeks of follow-up by late 2026. Initial data readout targeted at a medical conference in H2 2026.
• Expected during 2026 — Chicago flagship manufacturing site completion. The company’s primary regional manufacturing site in the Chicago area expected to complete construction during 2026 (per Q1 2026 press release, 11 May 2026).

---

Live Charts | Economic Calendar | Forum | Blog

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.